GLP‑1 drug response tied to genes

These drugs work by copying a gut hormone your body already makes after you eat. That hormone tells the brain “you’ve had enough” and slows how fast food leaves the stomach, which is why people often feel full sooner on semaglutide or tirzepatide. (nature.com) (sciencedirect.com) The problem is that the same weekly shot can look completely different from one person to the next. In the new study, some people reported losing less than 5% of their body weight, while others lost more than 20%, and nausea and vomiting ranged from absent to common. (mediacenter.23andme.com) (nature.com) To look for a reason, researchers ran a genome-wide association study, which is a giant compare-and-contrast search across DNA. They used self-reported treatment data from 27,885 people who had taken a glucagon-like peptide 1 drug for weight loss. (nature.com) The strongest weight-loss signal showed up in a gene called GLP1R. That gene is the instruction manual for the receptor these drugs are designed to hit, so the finding points straight at the drug’s front door. (nature.com) (scientificamerican.com) People carrying one copy of the helpful GLP1R variant were expected to lose about 0.76 kilograms more than non-carriers on these medicines. The variant is a missense change, which means one DNA letter swap slightly changes the protein’s shape, like filing one tooth on a key. (nature.com) (mediacenter.23andme.com) A second gene, GIPR, showed up on the side-effect side of the ledger. That gene helps cells respond to another gut signal, and the nausea-and-vomiting link appeared only in people taking tirzepatide, which targets both the glucagon-like peptide 1 receptor and the glucose-dependent insulinotropic polypeptide receptor. (nature.com) (mediacenter.23andme.com) That drug-specific split fits the biology. Semaglutide acts on the glucagon-like peptide 1 pathway alone, while tirzepatide also presses on the glucose-dependent insulinotropic polypeptide pathway, so a GIPR variant would be expected to matter more for tirzepatide than for semaglutide. (nature.com) (fda.gov) (accessdata.fda.gov) The researchers did not find a single “works” gene or a single “side effects” gene. They built a broader prediction model that mixed DNA with age, sex, body size, and other clinical details, then showed it could sort people into groups with different odds of bigger weight loss and different odds of nausea or vomiting. (nature.com) (mediacenter.23andme.com) This does not mean a cheek swab can already tell you exactly which obesity drug to take. The study used self-reported outcomes, and outside experts told Nature and Scientific American that genes explain only part of why one patient thrives while another quits after two months. (nature.com) (scientificamerican.com) But it does move obesity treatment a step closer to the way oncology already works. Instead of today’s trial-and-error routine, doctors could eventually use a mix of genetics and clinical history to estimate who is more likely to lose 15% of body weight, who may lose 5%, and who may need extra help with stomach side effects from the start. (nature.com 1) (nature.com 2)